BRISTOL-MYERS SQUIBB COMPANY Revenue
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Revenue of $12.97 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY revenues for the quarter ending 2026-06-30 was $12.97B, a 5.74% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY revenues for the quarter ending 2026-03-31 was $11.49B, a 2.57% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY revenues for the quarter ending 2025-12-31 was $12.50B, a 1.30% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY revenues for the quarter ending 2025-09-30 was $12.22B, a 2.77% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY revenues for fiscal 2025 was $48.19B, a 0.22% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY revenues for fiscal 2024 was $48.30B, a 7.32% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY revenues for fiscal 2023 was $45.01B, a 2.50% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY revenues for fiscal 2022 was $46.16B, a 0.49% decline from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.97B 10-Q · filed 2026-07-30 | $24.46B 10-Q · filed 2026-07-30 | $36.96B derived: sum of 3 quarters · filed 2026-07-30 | $49.19B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $11.49B 10-Q · filed 2026-04-30 | $23.99B derived: sum of 2 quarters · filed 2026-04-30 | $36.21B derived: sum of 3 quarters · filed 2026-04-30 | $48.48B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $12.50B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $24.72B derived: sum of 2 quarters · filed 2026-02-11 | $36.99B derived: sum of 3 quarters · filed 2026-07-30 | $48.19B 10-K · filed 2026-02-11 |
| 2025-09-30 | $12.22B 10-Q · filed 2025-10-30 | $24.49B derived: sum of 2 quarters · filed 2026-07-30 | $35.69B 10-Q · filed 2025-10-30 | $48.03B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $12.27B 10-Q · filed 2026-07-30 | $23.47B 10-Q · filed 2026-07-30 | $35.81B derived: sum of 3 quarters · filed 2026-07-30 | $47.70B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $11.20B 10-Q · filed 2026-04-30 | $23.54B derived: sum of 2 quarters · filed 2026-04-30 | $35.44B derived: sum of 3 quarters · filed 2026-04-30 | $47.64B derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $12.34B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $24.23B derived: sum of 2 quarters · filed 2026-02-11 | $36.44B derived: sum of 3 quarters · filed 2026-02-11 | $48.30B 10-K · filed 2026-02-11 |
| 2024-09-30 | $11.89B 10-Q · filed 2025-10-30 | $24.09B derived: sum of 2 quarters · filed 2025-10-30 | $35.96B 10-Q · filed 2025-10-30 | $47.44B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $12.20B 10-Q · filed 2025-07-31 | $24.07B 10-Q · filed 2025-07-31 | $35.54B derived: sum of 3 quarters · filed 2026-02-11 | $46.51B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $11.87B 10-Q · filed 2025-04-24 | $23.34B derived: sum of 2 quarters · filed 2026-02-11 | $34.31B derived: sum of 3 quarters · filed 2026-02-11 | $45.53B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $11.48B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $22.44B derived: sum of 2 quarters · filed 2026-02-11 | $33.67B derived: sum of 3 quarters · filed 2026-02-11 | $45.01B 10-K · filed 2026-02-11 |
| 2023-09-30 | $10.97B 10-Q · filed 2024-10-31 | $22.19B derived: sum of 2 quarters · filed 2024-10-31 | $33.53B 10-Q · filed 2024-10-31 | $44.94B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $11.23B 10-Q · filed 2024-07-26 | $22.56B 10-Q · filed 2024-07-26 | $33.97B derived: sum of 3 quarters · filed 2025-02-12 | $45.19B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $11.34B 10-Q · filed 2024-04-25 | $22.74B derived: sum of 2 quarters · filed 2025-02-12 | $33.96B derived: sum of 3 quarters · filed 2025-02-12 | $45.85B derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $11.41B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $22.62B derived: sum of 2 quarters · filed 2025-02-12 | $34.51B derived: sum of 3 quarters · filed 2025-02-12 | $46.16B 10-K · filed 2025-02-12 |
| 2022-09-30 | $11.22B 10-Q · filed 2023-10-26 | $23.11B derived: sum of 2 quarters · filed 2023-10-26 | $34.75B 10-Q · filed 2023-10-26 | $46.74B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $11.89B 10-Q · filed 2023-07-27 | $23.54B 10-Q · filed 2023-07-27 | $35.52B derived: sum of 3 quarters · filed 2024-02-13 | $47.14B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $11.65B 10-Q · filed 2023-04-27 | $23.63B derived: sum of 2 quarters · filed 2024-02-13 | $35.26B derived: sum of 3 quarters · filed 2024-02-13 | $46.96B derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $11.98B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $23.61B derived: sum of 2 quarters · filed 2024-02-13 | $35.31B derived: sum of 3 quarters · filed 2024-02-13 | $46.38B 10-K · filed 2024-02-13 |
| 2021-09-30 | $11.62B 10-Q · filed 2022-10-26 | $23.33B derived: sum of 2 quarters · filed 2022-10-26 | $34.40B 10-Q · filed 2022-10-26 | $45.47B derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | $11.70B 10-Q · filed 2022-07-27 | $22.78B 10-Q · filed 2022-07-27 | $33.84B derived: sum of 3 quarters · filed 2022-07-27 | $44.38B derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | $11.07B 10-Q · filed 2022-04-29 | $22.14B derived: sum of 2 quarters · filed 2022-04-29 | $32.68B derived: sum of 3 quarters · filed 2022-04-29 | $42.81B derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | $11.07B 10-K · filed 2021-02-10 | $21.61B derived: sum of 2 quarters · filed 2021-10-27 | $31.74B derived: sum of 3 quarters · filed 2021-10-27 | $42.52B 10-K · filed 2023-02-14 |
| 2020-09-30 | $10.54B 10-Q · filed 2021-10-27 | $20.67B derived: sum of 2 quarters · filed 2021-10-27 | $31.45B 10-Q · filed 2021-10-27 | $39.40B derived: sum of 4 quarters · filed 2021-10-27 |
| 2020-06-30 | $10.13B 10-Q · filed 2021-07-28 | $20.91B 10-Q · filed 2021-07-28 | $28.86B derived: sum of 3 quarters · filed 2021-07-28 | $34.86B derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $10.78B 10-Q · filed 2021-04-29 | $18.73B derived: sum of 2 quarters · filed 2021-04-29 | $24.73B derived: sum of 3 quarters · filed 2021-04-29 | $31.01B derived: sum of 4 quarters · filed 2021-04-29 |
| 2019-12-31 | $7.95B 10-K · filed 2021-02-10 | $13.95B derived: sum of 2 quarters · filed 2021-02-10 | $20.23B derived: sum of 3 quarters · filed 2021-02-10 | $26.14B 10-K · filed 2022-02-09 |
| 2019-09-30 | $6.01B 10-K · filed 2021-02-10 | $12.28B derived: sum of 2 quarters · filed 2021-02-10 | $18.20B 10-Q · filed 2020-11-05 | $24.17B derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $6.27B 10-K · filed 2021-02-10 | $12.19B 10-Q · filed 2020-08-06 | $18.17B derived: sum of 3 quarters · filed 2021-02-10 | $23.86B derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $5.92B 10-K · filed 2021-02-10 | $11.89B derived: sum of 2 quarters · filed 2021-02-10 | $17.58B derived: sum of 3 quarters · filed 2021-02-10 | $23.29B derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $5.97B 10-K · filed 2020-02-24 | $11.66B derived: sum of 2 quarters · filed 2020-02-24 | $17.37B derived: sum of 3 quarters · filed 2020-02-24 | $22.56B 10-K · filed 2021-02-10 |
| 2018-09-30 | $5.69B 10-K · filed 2020-02-24 | $11.39B derived: sum of 2 quarters · filed 2020-02-24 | $16.59B 10-Q · filed 2019-10-31 | $22.04B derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $5.70B 10-K · filed 2020-02-24 | $10.90B 10-Q · filed 2019-07-25 | $16.35B derived: sum of 3 quarters · filed 2020-02-24 | $21.60B derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $5.19B 10-K · filed 2020-02-24 | $10.64B derived: sum of 2 quarters · filed 2020-02-24 | $15.90B derived: sum of 3 quarters · filed 2020-02-24 | $21.04B derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $5.45B 10-K · filed 2019-02-25 | $10.70B derived: sum of 2 quarters · filed 2019-02-25 | $15.85B derived: sum of 3 quarters · filed 2019-02-25 | $20.78B 10-K · filed 2020-02-24 |
| 2017-09-30 | $5.25B 10-K · filed 2019-02-25 | $10.40B derived: sum of 2 quarters · filed 2019-02-25 | $15.33B derived: sum of 3 quarters · filed 2019-02-25 | |
| 2017-06-30 | $5.14B 10-K · filed 2019-02-25 | $10.07B derived: sum of 2 quarters · filed 2019-02-25 | ||
| 2017-03-31 | $4.93B 10-K · filed 2019-02-25 | |||
| 2016-12-31 | $19.43B 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |